News
BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W...
BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).
